T. Rowe Price Associates
QNCX icon

T. Rowe Price Associates’s Quince Therapeutics QNCX Stock Holding History

T. Rowe Price Associates’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-123
Closed -$55K – 3028
2022
Q2 		$55K Buy
123
+51
+71% +$36K ﹤0.01% 2845
2022
Q1 		$89K Sell
72
-7
-9% -$9.53K ﹤0.01% 2868
2021
Q4 		$201K Sell
79
-394
-83% -$2.4M ﹤0.01% 2760
2021
Q3 		$8.67M Buy
473
+276
+140% +$4.39M ﹤0.01% 1434
2021
Q2 		$2.09M Buy
+197
New +$1.65M ﹤0.01% 1722
2020
Q3 		– Sell
-386
Closed -$3.57M – 2618
2020
Q2 		$3.57M Sell
386
-31
-7% -$284K ﹤0.01% 1427
2020
Q1 		$3.8M Sell
417
-69
-14% -$681K ﹤0.01% 1377
2019
Q4 		$5.46M Buy
+486
New +$2.93M ﹤0.01% 1385

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

T. Rowe Price Associates's QNCX Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 123 shares — an estimated $55K sold.

T. Rowe Price Associates first reported a position in QNCX in Q4 2019 and held it in 8 quarters. The position peaked at $8.67M in Q3 2021. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

  • T. Rowe Price Associates reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 123 Quince Therapeutics shares in Q3 2022, an estimated $55K.
  • T. Rowe Price Associates first reported a position in Quince Therapeutics in Q4 2019 and held it in 8 quarters.
  • T. Rowe Price Associates's Quince Therapeutics position peaked at $8.67M in Q3 2021.
  • 58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.